Physician profile
Robert Nicholson
NPI 1124417373
$1,462.65
in general payments reported to CMS, 2019-2025
11 companies · $385 in 2025
The $385 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $186 · 2021: $30.45 · 2022: $32.71 · 2023: $347 · 2024: $482 · 2025: $385.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,213.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,213.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $367.96 | 2020-2025 | Xtampza, Belbuca |
| Valinor Pharma, LLC | $302.79 | 2024-2025 | Movantik |
| Forte Bio-Pharma LLC | $242.36 | 2023-2025 | Prolate, Nalocet, Tanlor |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $197.78 | 2020-2025 | Relistor, Aldara |
| Scilex Pharmaceuticals INC. | $98.73 | 2023-2025 | Ztlido |
| Novartis Pharmaceuticals Corporation | $94.12 | 2020 | |
| Virtus Pharmaceuticals LLC | $75.22 | 2023 | Levorphanol Tartrate |
| Sentynl Therapeutics, INC. | $24.47 | 2020 | |
| Vertex Pharmaceuticals Incorporated | $23.70 | 2025 | |
| Hikma Pharmaceuticals USA | $18.32 | 2024 | Kloxxado |
| Nevro Corp. | $17.20 | 2024 | Senza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Nicholson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.